ReachRxResearch
Home
Research
Sign Up
How do I manage candiduria: practical algorithms and remaining conundrums in 2026
Back to Research Hub
  1. Home
  2. Research Hub
  3. How do I manage candiduria: practical al…

How do I manage candiduria: practical algorithms and remaining conundrums in 2026

Clinical Microbiology and Infection·October 13
Infectious DiseasesLimited evidenceCandiduriaInvasive CandidiasisUrinary Tract InfectionNarrative ReviewAntifungal AgentAdultFluconazole

Summary

View source

What was studied

A narrative review evaluating how to diagnose and manage candiduria across clinical scenarios — from asymptomatic colonization to invasive candidiasis — using a clinical vignette of a patient with a double-J ureteral stent and acute febrile illness, grounded in 2016 IDSA and 2025 ECMM guidelines.

Key findings

No randomized controlled trials exist for symptomatic candiduria management; the review synthesizes observational data and expert guidance into practical clinical algorithms covering risk stratification, antifungal selection (based on renal diffusion and urinary excretion profiles), and management of rare complications like fungus balls.

Study limitations

Evidence base relies entirely on observational studies and expert opinion, with no RCTs addressing symptomatic candiduria treatment; findings are framed around a single clinical vignette, which may limit generalizability across diverse patient populations.

Clinical implications

Distinguish colonization from true infection before initiating antifungals — most candiduria in hospitalized patients does not require treatment. When treatment is warranted, choose antifungals based on their urinary excretion profile (e.g., fluconazole excretes well renally) and apply antifungal stewardship principles, especially in ICU and urological settings.

Caveats

  • Antifungal stewardship implications are significant — overtreatment of asymptomatic candiduria remains a common real-world problem, and this review's algorithms have not been prospectively validated
  • No randomized controlled trials exist on symptomatic candiduria management; all treatment recommendations rest on observational data and expert consensus, which limits confidence in specific antifungal choices and thresholds for treatment
  • The clinical framework is built around a single illustrative vignette (double-J stent patient), which may not reflect the full range of candiduria presentations encountered in practice

Related Questions

Explore related topics

Which antifungal agents achieve adequate urinary concentrations for treating Candida UTI?When should candiduria in ICU patients be treated versus monitored?How do the 2025 ECMM guidelines differ from the 2016 IDSA guidelines on candiduria management?

Publication Details

Year
2026
Journal
Clinical Microbiology and Infection
Source
View article
Keep scrolling
More content below.
Up Next